This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights: Pfizer
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer
The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon Communications, Chevron, Pfizer and 3M Company
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Exxon Mobil, Verizon Communications, Chevron, Pfizer and 3M Company
Stock Market News for June 2, 2020
by Zacks Equity Research
Benchmarks closed in the green on Monday as signs of economic rebound overshadowed civil unrest amid coronavirus pandemic and rising U.S.-China tensions.
Top Research Reports for Pfizer, Comcast & salesforce
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Comcast (CMCSA) and salesforce.com (CRM).
Monday Market Indexes Stay in Green on So-So Data
by Mark Vickery
The Dow posted is first day higher in the last 3 days -- finishing +0.36% as of the closing bell. The S&P 500 went up likewise: +0.38%.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.
5 Dogs of the Dow for the Month of June
by Tirthankar Chakraborty
Dogs of the Dow have large customer base, sustainable business model, a long track of profitability and strong liquidity, which allow them to offer sizable yields regardless of market conditions.
Drugmakers Focus on Coronavirus Vaccine by 2020: 4 Winners
by Ritujay Ghosh
Clinical trials of non-COVID-19 drugs have taken a backseat as most drugmakers and biotechnology companies are speeding up development of a vaccine for the novel coronavirus.
Merck (MRK) Shares Looking Ripe For A Buy
by Daniel Laboe
Merck (MRK) is a pharmaceutical powerhouse that has been under-appreciated amid this health crisis
4 Stocks to Watch as Dow Breezes Past 25,000 Points
by Zacks Equity Research
Dow Jones' journey past 25,000 points this week could mark the beginning of a series of gains ahead, owing to some major tailwinds.
Pfizer (PFE) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Inks 10-Year Deal With Arcus for Immuno-oncology Drugs
by Zacks Equity Research
Gilead (GILD) looks to expand presence in the immune-oncology space with a 10-year partnership with Arcus.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novavax, Moderna, Pfizer, Gilead and Vir Biotechnology
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
Merck Inks 3 Deals for Coronavirus Anti-infective & Vaccines
by Zacks Equity Research
Merck (MRK) to buy Themis, which is making a COVID-19 vaccine. It is also buying global rights to a private biotech's antiviral candidate, EIDD-2801, which is in early clinical studies to treat COVID-19.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Coronavirus Vaccine Efforts Continue, Novavax Begins Human Trial
by Kinjel Shah
As several pharma/biotech companies speed up efforts to make a vaccine for COVID-19, Novavax (NVAX) begins human testing of its candidate, NVX-CoV2373.
Novavax Begins Clinical Study for Coronavirus Vaccine
by Zacks.com
Novavax (NVAX) enrolls the first set of participants in a phase I/II clinical study for evaluating its coronavirus vaccine candidate, NVX-CoV2373.
Is Pfizer (PFE) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Gilead (GILD) Gains 13% YTD on Coronavirus Drug Development
by Zacks Equity Research
Gilead's experimental coronavirus drug, remdesivir, shows promise. The stock has been in news since the onset of the year on updates from the same.
Pharma Stock Roundup: FDA Ok's Cancer Drugs for New Use, JNJ Stops US Baby Powder Sales
by Kinjel Shah
FDA approves line extensions for Bristol-Myers (BMY), Roche (RHHBY) and AstraZeneca (AZN)/Merck's (MRK) drugs. J&J stops sales of talc-based baby powders in the United States and Canada.
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
by Ritujay Ghosh
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
Gilead, Galapagos Announce Positive Data on Inflammatory Drug
by Zacks Equity Research
Gilead (GILD) and Galapagos announce positive data on filgotinib for the treatment of ulcerative colitis.